Related references
Note: Only part of the references are listed.Recent advances in PI3K/PKB/mTOR inhibitors as new anticancer agents
Maria Antonietta Occhiuzzi et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2023)
P-glycoprotein Mediates Resistance to the Anaplastic Lymphoma Kinase Inhiitor Ensartinib in Cancer Cells
Chung-Pu Wu et al.
CANCERS (2022)
DHW-221, a Dual PI3K/mTOR Inhibitor, Overcomes Multidrug Resistance by Targeting P-Glycoprotein (P-gp/ABCB1) and Akt-Mediated FOXO3a Nuclear Translocation in Non-small Cell Lung Cancer
Mingyue Liu et al.
FRONTIERS IN ONCOLOGY (2022)
The WD repeat-containing protein 5 (WDR5) antagonist WDR5-0103 restores the efficacy of cytotoxic drugs in multidrug-resistant cancer cells overexpressing ABCB1 or ABCG2
Chung-Pu Wu et al.
BIOMEDICINE & PHARMACOTHERAPY (2022)
HS-173, a selective PI3K inhibitor, induces cell death in head and neck squamous cell carcinoma cell lines
Elisabeth Foki et al.
WIENER KLINISCHE WOCHENSCHRIFT (2021)
The inhibitors of KDM4 and KDM6 histone lysine demethylases enhance the anti-growth effects of erlotinib and HS-173 in head and neck cancer cells
Robert Kleszcz et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2021)
ABCB1 and ABCG2 restricts the efficacy of gedatolisib (PF-05212384), a PI3K inhibitor in colorectal cancer cells
Changfu Liu et al.
CANCER CELL INTERNATIONAL (2021)
Overexpression of Human ABCB1 and ABCG2 Reduces the Susceptibility of Cancer Cells to the Histone Deacetylase 6-Specific Inhibitor Citarinostat
Chung-Pu Wu et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Properties of FDA-approved small molecule phosphatidylinositol 3-kinase inhibitors prescribed for the treatment of malignancies
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2021)
ABCG2 transports anticancer drugs via a closed-to-open switch
Benjamin J. Orlando et al.
NATURE COMMUNICATIONS (2020)
A dual PI3 kinase/mTOR inhibitor BEZ235 reverses doxorubicin resistance in ABCB1 overexpressing ovarian and pancreatic cancer cell lines
David E. Durrant et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS (2020)
Overexpression of ABCB1 and ABCG2 contributes to reduced efficacy of the PI3K/mTOR inhibitor samotolisib (LY3023414) in cancer cell lines
Chung-Pu Wu et al.
BIOCHEMICAL PHARMACOLOGY (2020)
Low dose novel PARP-PI3K inhibition via nanoformulation improves colorectal cancer immunoradiotherapy
M. R. Landry et al.
MATERIALS TODAY BIO (2020)
HS-173 as a novel inducer of RIP3-dependent necroptosis in lung cancer
Jung Hee Park et al.
CANCER LETTERS (2019)
Rationale for Using Irreversible Epidermal Growth Factor Receptor Inhibitors in Combination with Phosphatidylinositol 3-Kinase Inhibitors for Advanced Head and Neck Squamous Cell Carcinoma
Nicole L. Michmerhuizen et al.
MOLECULAR PHARMACOLOGY (2019)
Structural insight into substrate and inhibitor discrimination by human P-glycoprotein
Amer Alam et al.
SCIENCE (2019)
PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside
Ali S. Alzahrani
SEMINARS IN CANCER BIOLOGY (2019)
Human ATP-binding cassette transporters ABCB1 and ABCG2 confer resistance to histone deacetylase 6 inhibitor ricolinostat (ACY-1215) in cancer cell lines
Chung-Pu Wu et al.
BIOCHEMICAL PHARMACOLOGY (2018)
Revisiting the role of ABC transporters in multidrug-resistant cancer
Robert W. Robey et al.
NATURE REVIEWS CANCER (2018)
Overcoming ABC transporter-mediated multidrug resistance: The dual role of tyrosine kinase inhibitors as multitargeting agents
Giovanni Luca Beretta et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)
Dual effects of the PI3K inhibitor ZSTK474 on multidrug efflux pumps in resistant cancer cells
Divya Muthiah et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2017)
Clinical use of PI3K inhibitors in B-cell lymphoid malignancies: today and tomorrow
I. B. Greenwell et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2017)
Structure of the human multidrug transporter ABCG2
Nicholas M. I. . Taylor et al.
NATURE (2017)
Radiosensitization of the PI3K inhibitor HS-173 through reduction of DNA damage repair in pancreatic cancer
Jung Hee Park et al.
ONCOTARGET (2017)
Tumor vessel normalization by the PI3K inhibitor HS-173 enhances drug delivery
Soo Jung Kim et al.
CANCER LETTERS (2017)
The PI3K/mTOR dual inhibitor BEZ235 suppresses proliferation and migration and reverses multidrug resistance in acute myeloid leukemia
Lan Deng et al.
ACTA PHARMACOLOGICA SINICA (2017)
Human ATP-Binding Cassette Transporter. ABCG2 Confers Resistance to CUDC-907, a Dual Inhibitor of Histone Deacetylase and Phosphatidylinositol 3-Kinase
Chung-Pu Wu et al.
MOLECULAR PHARMACEUTICS (2016)
Osimertinib (AZD9291) Attenuates the Function of Multidrug Resistance-Linked ATP-Binding Cassette Transporter ABCB1 in Vitro
Sung-Han Hsiao et al.
MOLECULAR PHARMACEUTICS (2016)
HS-173, a novel PI3K inhibitor suppresses EMT and metastasis in pancreatic cancer
Marufa Rumman et al.
ONCOTARGET (2016)
Human ATP-Binding Cassette Transporter ABCB1 Confers Resistance to Volasertib (BI 6727), a Selective Inhibitor of Polo-like Kinase 1
Chung-Pu Wu et al.
MOLECULAR PHARMACEUTICS (2015)
Overexpression of Human ABCB1 in Cancer Cells Leads to Reduced Activity of GSK461364, a Specific Inhibitor of Polo-like Kinase 1
Chung-Pu Wu et al.
MOLECULAR PHARMACEUTICS (2014)
Overexpression of ATP-binding cassette transporter ABCG2 as a potential mechanism of acquired resistance to vemurafenib in BRAF(V600E) mutant cancer cells
Chung-Pu Wu et al.
BIOCHEMICAL PHARMACOLOGY (2013)
Human ABCB1 (P-glycoprotein) and ABCG2 mediate resistance to BI 2536, a potent and selective inhibitor of Polo-like kinase 1
Chung-Pu Wu et al.
BIOCHEMICAL PHARMACOLOGY (2013)
Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway
Howard A. Burris
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
HS-173, a novel phosphatidylinositol 3-kinase (PI3K) inhibitor, has anti-tumor activity through promoting apoptosis and inhibiting angiogenesis
Hyunseung Lee et al.
CANCER LETTERS (2013)
Synergistic anticancer activity of HS-173, a novel PI3K inhibitor in combination with Sorafenib against pancreatic cancer cells
Sun-Mi Yun et al.
CANCER LETTERS (2013)
A novel PI3K inhibitor alleviates fibrotic responses in fibroblasts derived from Peyronie's plaques
Kyung Hee Jung et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2013)
A novel imidazopyridine PI3K inhibitor with anticancer activity in non-small cell lung cancer cells
Hyunseung Lee et al.
ONCOLOGY REPORTS (2013)
HS-173, a Novel PI3K Inhibitor, Attenuates the Activation of Hepatic Stellate Cells in Liver Fibrosis
Mi Kwon Son et al.
SCIENTIFIC REPORTS (2013)
Inhibition of phosphoinositide-3 kinase pathway down regulates ABCG2 function and sensitizes malignant pleural mesothelioma to chemotherapy
Bruno Fischer et al.
LUNG CANCER (2012)
Perifosine downregulates MDR1 gene expression and reverses multidrug-resistant phenotype by inhibiting PI3K/Akt/NF-κB signaling pathway in a human breast cancer cell line
X. Lin et al.
NEOPLASMA (2012)
Improving Cancer Chemotherapy with Modulators of ABC Drug Transporters
S. Shukla et al.
CURRENT DRUG TARGETS (2011)
Phase I Trial of Lenalidomide and CCI-779 in Patients With Relapsed Multiple Myeloma: Evidence for Lenalidomide-CCI-779 Interaction via P-Glycoprotein
Craig C. Hofmeister et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties
C. Hegedus et al.
BRITISH JOURNAL OF PHARMACOLOGY (2009)
PI3K Pathway Activation Mediates Resistance to MEK Inhibitors in KRAS Mutant Cancers
Susan Wee et al.
CANCER RESEARCH (2009)
PTEN/PI3K/Akt Pathway Regulates the Side Population Phenotype and ABCG2 Activity in Glioma Tumor Stem-like Cells
Anne-Marie Bleau et al.
CELL STEM CELL (2009)
Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1®
Robert W. Robey et al.
BIOCHEMICAL PHARMACOLOGY (2008)
Evidence for dual mode of action of a thiosemicarbazone, NSC73306: a potent substrate of the multidrug resistance-linked ABCG2 transporter
Chung-Pul Wu et al.
MOLECULAR CANCER THERAPEUTICS (2007)
ABCG2 expression, function, and promoter methylation in human multiple myeloma
Joel G. Turner et al.
BLOOD (2006)
MDR-1, but not MDR-3 gene expression, is associated with unmutated IgVH genes and poor prognosis chromosomal aberrations in chronic lymphocytic leukemia
Christine Matthews et al.
LEUKEMIA & LYMPHOMA (2006)
Human multidrug resistance ABCB and ABCG transporters:: Participation in a chemoimmunity defense system
Balazs Sarkadi et al.
PHYSIOLOGICAL REVIEWS (2006)
Complex interaction of BCRP/ABCG2 and imatinib in BCR-ABL-expressing cells: BCRP-mediated resistance to imatinib is attenuated by imatinib-induced reduction of BCRP expression
Takeo Nakanishi et al.
BLOOD (2006)
A high-throughput cell-based assay for inhibitors of ABCG2 activity
CJ Henrich et al.
JOURNAL OF BIOMOLECULAR SCREENING (2006)
BCRP mRNA expression v. clinical outcome in 40 adult AML patients
B Uggla et al.
LEUKEMIA RESEARCH (2005)
Breast cancer resistance protein impacts clinical outcome in platinum-based chemotherapy for advanced non-small cell lung cancer
K Yoh et al.
CLINICAL CANCER RESEARCH (2004)
Pheophorbide a is a specific probe for ABCG2 function and inhibition
RW Robey et al.
CANCER RESEARCH (2004)
ABCG2 mediates differential resistance to SN-38 (7-ethyl-10-hydroxycamptothecin) and homocamptothecins
SE Bates et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2004)
Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity
RW Robey et al.
BRITISH JOURNAL OF CANCER (2003)
The role of multidrug, transporters in drug availability, metabolism and toxicity
A Bodó et al.
TOXICOLOGY LETTERS (2003)
Serum-derived protein S binds to phosphatidylserine and stimulates the phagocytosis of apoptotic cells
HA Anderson et al.
NATURE IMMUNOLOGY (2003)
BCRP gene expression is associated with a poor response to remission induction therapy in childhood acute myeloid leukemia
D Steinbach et al.
LEUKEMIA (2002)
Multidrug resistance in cancer: Role of ATP-dependent transporters
MM Gottesman et al.
NATURE REVIEWS CANCER (2002)
Functional characterization of glycosylation-deficient human P-glycoprotein using a vaccinia virus expression system
JJ Gribar et al.
JOURNAL OF MEMBRANE BIOLOGY (2000)
Share Paper
